Recently, repurposing bumetanide as an AD medication was proposed based on data that showed bumetanide “reversed” APOE genotype-dependent transcriptomic signatures in mouse and cell culture models (Taubes et al., 2021). The gene discussed is APOE; the disease is Alzheimer disease.